Top Clinical Trials companies in the world by Revenue Per Share

This ranking features the top 417 Clinical Trials companies in the world ranked by Revenue Per Share, averaging a Revenue Per Share of USD 165.64, for January 15, 2025.

Global

Clinical Trials

#	Name	Revenue Per Share	Reported Date	Stock Price	Change	Country
1	Cingulate Inc. 1 CING	USD 68,343.25	Sept. 30, 2023	USD 4.62	-0.22%	United States
2	ICON Public Limited Company 2 ICLR	USD 98.90	Dec. 31, 2023	USD 200.24	-8.14%	Ireland
3	Charles River Laboratories International, Inc. 3 CRL	USD 78.97	Sept. 28, 2024	USD 178.08	-6.34%	United States
4	Medpace Holdings, Inc. 4 MEDP	USD 67.02	Sept. 30, 2024	USD 330.91	-5.99%	United States
5	Vertex Pharmaceuticals Incorporated 5 VRTX	USD 41.13	Sept. 30, 2024	USD 411.66	-0.41%	United States
6	Genmab A/S 6 GMAB.CO	USD 37.34	Dec. 31, 2023	USD 216.88	1.28%	Denmark
7	Neurocrine Biosciences, Inc. 7 NBIX	USD 22.42	Sept. 30, 2024	USD 139.51	-2.46%	United States
8	Incyte Corporation 8 INCY	USD 18.97	Sept. 30, 2024	USD 71.93	-0.61%	United States
9	BioNTech SE 9 22UA.F	USD 17.52	Dec. 31, 2023	USD 116.36	-0.45%	Germany
10	Sarepta Therapeutics, Inc. 10 SRPT	USD 17.38	Sept. 30, 2024	USD 118.83	0.34%	United States
11	Atara Biotherapeutics, Inc. 11 ATRA	USD 17.05	Sept. 30, 2024	USD 12.31	-23.96%	United States
12	Alnylam Pharmaceuticals, Inc. 12 ALNY	USD 16.52	Sept. 30, 2024	USD 240.51	-6.88%	United States
13	Precision BioSciences, Inc. 13 DTIL	USD 12.88	Sept. 30, 2024	USD 5.38	-6.27%	United States
14	Supernus Pharmaceuticals, Inc. 14 SUPN	USD 11.88	Sept. 30, 2024	USD 37.82	0.66%	United States
15	Castle Biosciences, Inc. 15 CSTL	USD 11.34	Sept. 30, 2024	USD 25.46	-2.64%	United States
16	Rigel Pharmaceuticals, Inc. 16 RIGL	USD 9.12	Sept. 30, 2024	USD 16.69	-2.46%	United States
17	Krystal Biotech, Inc. 17 KRYS	USD 8.49	Sept. 30, 2024	USD 142.64	-5.10%	United States
18	Agenus Inc. 18 AGEN	USD 7.86	Sept. 30, 2024	USD 3.15	-0.32%	United States
19	Burning Rock Biotech Limited 19 BNR	USD 7.39	Dec. 31, 2023	USD 6.55	-6.69%	China
20	Axsome Therapeutics, Inc. 20 AXSM	USD 7.11	Sept. 30, 2024	USD 84.60	-5.23%	United States
21	Exelixis, Inc. 21 EXEL	USD 7.03	Sept. 27, 2024	USD 35.65	0.99%	United States
22	Blueprint Medicines Corporation 22 BPMC	USD 6.99	Sept. 30, 2024	USD 102.56	-0.77%	United States
23	Mirum Pharmaceuticals, Inc. 23 MIRM	USD 6.51	Sept. 30, 2024	USD 43.32	-1.54%	United States
24	Corcept Therapeutics Incorporated 24 CORT	USD 6.11	Sept. 30, 2024	USD 51.66	1.18%	United States
25	Intra-Cellular Therapies, Inc. 25 ITCI	USD 6.09	Sept. 30, 2024	USD 126.89	-0.24%	United States
26	Guardant Health, Inc. 26 GH	USD 5.70	Sept. 30, 2024	USD 37.46	-1.68%	United States
27	Cartesian Therapeutics, Inc. 27 RNAC	USD 5.57	Sept. 30, 2024	USD 18.02	-1.69%	United States
28	Protagonist Therapeutics, Inc. 28 PTGX	USD 5.30	Sept. 30, 2024	USD 36.67	-1.26%	United States
29	Immunocore Holdings plc 29 IMCR	USD 5.10	Dec. 31, 2023	USD 28.56	-4.90%	United Kingdom
30	NeoGenomics, Inc. 30 NEO	USD 5.10	Sept. 30, 2024	USD 13.78	9.11%	United States
31	HOOKIPA Pharma Inc. 31 HOOK	USD 4.21	Sept. 30, 2024	USD 1.86	4.49%	United States
32	Shin Nippon Biomedical Laboratories, Ltd. 32 2395.T	USD 4.20	March 31, 2024	USD 10.78	1.91%	Japan
33	Vivos Therapeutics, Inc. 33 VVOS	USD 4.17	Sept. 30, 2024	USD 5.06	4.33%	United States
34	GNI Group Ltd. 34 2160.T	USD 3.86	Dec. 31, 2023	USD 19.77	1.11%	Japan
35	Madrigal Pharmaceuticals, Inc. 35 MDGL	USD 3.74	Sept. 30, 2024	USD 274.12	-9.74%	United States
36	Immuneering Corporation 36 IMRX	USD 3.41	Sept. 30, 2023	USD 1.95	-2.99%	United States
37	electroCore, Inc. 37 ECOR	USD 3.29	Sept. 30, 2024	USD 15.60	0.97%	United States
38	Exagen Inc. 38 XGN	USD 3.09	Sept. 30, 2024	USD 3.00	-3.85%	United States
39	Arcus Biosciences, Inc. 39 RCUS	USD 3.06	Sept. 30, 2024	USD 13.82	-0.79%	United States
40	Voyager Therapeutics, Inc. 40 VYGR	USD 3.02	Sept. 30, 2024	USD 5.05	-4.36%	United States
41	PhoenixBio Co., Ltd. 41 6190.T	USD 3.00	March 31, 2024	USD 2.06	-4.87%	Japan
42	Arcellx, Inc. 42 ACLX	USD 2.93	Sept. 30, 2024	USD 64.65	-4.02%	United States
43	Zai Lab Limited 43 9688.HK	USD 2.76	Dec. 31, 2023	USD 2.49	0.18%	China
44	Pulmatrix, Inc. 44 PULM	USD 2.74	Sept. 30, 2024	USD 5.90	-1.50%	United States
45	MDxHealth SA 45 MDXH	USD 2.71	Dec. 31, 2023	USD 2.00	NA	Belgium
46	Travere Therapeutics, Inc. 46 TVTX	USD 2.63	Sept. 30, 2024	USD 17.07	-8.18%	United States
47	Sonnet BioTherapeutics Holdings, Inc. 47 SONN	USD 2.53	Sept. 30, 2024	USD 1.52	-3.80%	United States
48	Denali Therapeutics Inc. 48 DNLI	USD 2.51	Sept. 30, 2023	USD 18.74	-4.34%	United States
49	Legend Biotech Corporation 49 LEGN	USD 2.50	June 30, 2024	USD 31.64	-2.65%	United States
50	Celularity Inc. 50 CELU	USD 2.32	Sept. 30, 2024	USD 2.10	1.45%	United States

1 2 3 4 … 9

Frequently Asked Questions

Which Clinical Trials company has the highest Revenue Per Share ?

The Clinical Trials company with the highest Revenue Per Share is Cingulate Inc. (NasdaqCM: CING) at USD 68,343.25.
Which Clinical Trials company has the lowest Revenue Per Share ?

The Clinical Trials company with the lowest Revenue Per Share is MedPacto, Inc. (KOSDAQ: 235980.KQ) at USD 0.00.

What are the top 10 Clinical Trials companies by Revenue Per Share ?

The top 10 Clinical Trials companies the Global by Revenue Per Share are Cingulate Inc., ICON Public Limited Company, Charles River Laboratories International, Inc., Medpace Holdings, Inc., Vertex Pharmaceuticals Incorporated, Genmab A/S, Neurocrine Biosciences, Inc., Incyte Corporation, BioNTech SE and Sarepta Therapeutics, Inc..
What are the bottom 10 Clinical Trials companies by Revenue Per Share ?

The bottom 10 Clinical Trials companies by Revenue Per Share are MedPacto, Inc., Faron Pharmaceuticals Oy, FibroBiologics, Inc. Common Stock, GH Research PLC, Tharimmune, Inc., Genenta Science S.p.A., GT Biopharma, Inc., ImmuPharma plc, Savara Inc. and Immunic, Inc..